CoChat

Safety and effect of transforming growth factor‐β2 for treatment of venous stasis ulcers

Robson, M. C., Phillip, L. G., Cooper, D. M., Lyle, W. G., Robson, L. E., Odom, L., Hill, D. P., Hanham, A. F., Ksander, G. A. · 1995 · Wound Repair and Regeneration
Cited by 94

The DOI matches its Crossref record.

Abstract

Transforming growth factor‐β 2 promotes healing in a variety of animal models and exhibits clinical effects thought to be mediated by connective tissue formation. Two clinical trials were conducted to evaluate the safety and effect of transforming growth factor‐β 2 purified from bovine bone and delivered topically to venous stasis ulcers three times per week for up to 6 weeks by means of a lyophilized collagen vehicle. The first was an open‐label trial comparing transforming growth factor‐β 2 purified from bovine bone (0.5 µg/cm 2) with a placebo consisting of lyophilized collagen vehicle‐without active drug. After no safety issues arose in that trial, a prospectively randomized, closed‐label, observer‐blinded, three‐armed trial was conducted to compare bovine transforming growth factor‐β 2 (2.5 µg/cm 2) with the collagen matrix placebo vehicle and with a standard dressing. Standardized elastic compression was applied to all test extremities. The rate of reduction of ulcer area as measured by planimetry was the primary measure of effect. No serious safety‐related events occurred in either trial. Clinical evaluation suggested that improvement in the quality and quantity of granulation tissue appeared to precede epithelialization of ulcers treated with bovine transforming growth factor‐β 2. In both studies, treatment with bovine transforming growth factor‐β 2 appeared to have a positive effect on the rate of ulcer closure, whereas ulcers in the control groups continued to exhibit impaired healing. In the open‐label study, the mean rate of closure of ulcers treated with bovine transforming growth factor‐β 2 was significantly greater than that of ulcers treated with placebo. There was likewise enhanced reduction in ulcer area in the ulcers treated with bovine transforming growth factor‐β 2 in the second trial. However, because of a higher variability in patient response and a greater placebo effect, the difference was not significant. The placebo was not worse than the standard care arm, thereby showing that the vehicle is not injurious to healing. The combined results of the two trials suggest that, at doses of 0.5 to 2.5 µg/cm 2, bovine transforming growth factor‐β 2 is safe as a topically applied agent in a collagen matrix vehicle and can have a positive effect on closure of venous stasis ulcers. Large multicenter trials appear to be indicated to evaluate fully the potential utility of transforming growth factor‐β 2 in accelerating closure of chronic dermal ulcers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1524-475x.1995.30207.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 94

Metadata

Authors
Robson, M. C., Phillip, L. G., Cooper, D. M., Lyle, W. G., Robson, L. E., Odom, L., Hill, D. P., Hanham, A. F., & Ksander, G. A.
Venue
Wound Repair and Regeneration
Publisher
Wiley
Published
1995-04
Volume
3
Issue
2
Pages
157-167
ISSN
  • 1067-1927 (ISSN-L)
  • 1524-475X
OpenAlex
W2009969959
Cited by
94
References
0
FWCI
5.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Safety and effect of transforming growth factor‐β2 for treatment of venous stasis ulcers. https://app.cochat.ai/papers/10.1046/j.1524-475x.1995.30207.x
The paper
Robson, M. C., Phillip, L. G., Cooper, D. M., Lyle, W. G., Robson, L. E., Odom, L., Hill, D. P., Hanham, A. F., & Ksander, G. A. (1995). Safety and effect of transforming growth factor‐β2 for treatment of venous stasis ulcers. Wound Repair and Regeneration. https://doi.org/10.1046/j.1524-475x.1995.30207.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.